» Articles » PMID: 18553568

Diagnostic and Mutational Spectrum of Progressive Osseous Heteroplasia (POH) and Other Forms of GNAS-based Heterotopic Ossification

Overview
Specialty Genetics
Date 2008 Jun 17
PMID 18553568
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Progressive osseous heteroplasia (POH) is a rare, disabling disease of heterotopic ossification (HO) that progresses from skin and subcutaneous tissues into deep skeletal muscle. POH occurs in the absence of multiple developmental features of Albright hereditary osteodystrophy (AHO) or hormone resistance, clinical manifestations that are also associated with GNAS inactivation. However, occasional patients with AHO and pseudohypoparathyroidism 1a/c (PHP1a/c; AHO features plus hormone resistance) have also been described who have progressive HO. This study was undertaken to define the diagnostic and mutational spectrum of POH and progressive disorders of HO, and to distinguish them from related disorders in which HO remains confined to the skin and subcutaneous tissues. We reviewed the charts of 111 individuals who had cutaneous and subcutaneous ossification. All patients were assessed for eight characteristics: age of onset of HO, presence and location of HO, depth of HO, type of HO, progression of HO, features of AHO, PTH resistance, and GNAS mutation analysis. We found, based on clinical criteria, that POH and progressive HO syndromes are at the severe end of a phenotypic spectrum of GNAS-inactivating conditions associated with extra-skeletal ossification. While most individuals with superficial or progressive ossification had mutations in GNAS, there were no specific genotype-phenotype correlations that distinguished the more progressive forms of HO (e.g., POH) from the non-progressive forms (osteoma cutis, AHO, and PHP1a/c).

Citing Articles

Contract to kill: GNAS mutation.

Raut P, Mathivanan P, Batra S, Ponnusamy M Mol Cancer. 2025; 24(1):70.

PMID: 40050874 PMC: 11887407. DOI: 10.1186/s12943-025-02247-4.


Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.

Li J, Dang Y, Liu M, Gao L, Lin H Int J Biol Sci. 2025; 21(2):544-564.

PMID: 39781450 PMC: 11705629. DOI: 10.7150/ijbs.102297.


Progressive osseous heteroplasia in a five-month-old boy with a mutation in exon 9 of : a case report.

Jiang L, Li Z Am J Transl Res. 2024; 16(11):6835-6840.

PMID: 39678607 PMC: 11645640. DOI: 10.62347/WVMV7029.


The role of miRNAs as biomarkers in heterotopic ossification.

Xie C, Liu X, Li W, Yao Z, Men H, Li Z EFORT Open Rev. 2024; 9(12):1120-1133.

PMID: 39620561 PMC: 11619732. DOI: 10.1530/EOR-22-0100.


Hair follicle-resident progenitor cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.

McMullan P, Maye P, Root S, Yang Q, Edie S, Rowe D bioRxiv. 2024; .

PMID: 38948860 PMC: 11213030. DOI: 10.1101/2024.06.18.599506.


References
1.
Weinstein L . The stimulatory G protein alpha-subunit gene: mutations and imprinting lead to complex phenotypes. J Clin Endocrinol Metab. 2001; 86(10):4622-6. DOI: 10.1210/jcem.86.10.8007. View

2.
Kaplan F, Craver R, MacEwen G, Gannon F, Finkel G, Hahn G . Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow-up of three previously reported cases. J Bone Joint Surg Am. 1994; 76(3):425-36. View

3.
Shapira H, Mouallem M, Shapiro M, Weisman Y, Farfel Z . Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. Hum Genet. 1996; 97(1):73-5. DOI: 10.1007/BF00218836. View

4.
Patten J, JOHNS D, Valle D, Eil C, Gruppuso P, Steele G . Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med. 1990; 322(20):1412-9. DOI: 10.1056/NEJM199005173222002. View

5.
Aldred M, Trembath R . Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat. 2000; 16(3):183-9. DOI: 10.1002/1098-1004(200009)16:3<183::AID-HUMU1>3.0.CO;2-L. View